Loading organizations...
§ Public · Gaithersburg, MD, USA
Sensei Biotherapeutics is a technology company.
Sensei Biotherapeutics is a clinical-stage biotechnology company developing next-generation cancer therapeutics. It precisely interacts with the tumor microenvironment to redirect the immune system against malignancies. Its investigational medicines leverage the body's own defenses, translating immunological insights into novel treatment strategies.
The company’s foundation arises from recognizing that modulating the immune system offers a powerful avenue against cancer. While specific founding details are not extensively published, Sensei Biotherapeutics strategically evolved through acquisitions like Faeth Therapeutics. This expansion bolstered capabilities, enabling diverse pipeline advancement via novel immunological principles within the complex tumor landscape.
Sensei Biotherapeutics ultimately serves cancer patients, striving for more effective treatments. Its vision centers on delivering transformative, immune-directed therapies that re-engineer the relationship between the immune system and cancer. The company dedicates itself to inspiring the body to fight disease, aiming for superior therapeutic outcomes and improved patient lives.
Sensei Biotherapeutics has raised $59.0M across 2 funding rounds.
Sensei Biotherapeutics has raised $59.0M in total across 2 funding rounds.
Sensei Biotherapeutics has raised $59.0M in total across 2 funding rounds.
Sensei Biotherapeutics's investors include Christian Angermayer, Catalio Capital, Helium-3 Ventures, Inveready Technology Investment Group, MMC Ventures, Platanus Ventures, Presight Capital, Valar Ventures, Christian Woolfenden, Matt Bellamy, Richard Fearn, Cambrian Biopharma.
Sensei Biotherapeutics has raised $59.0M across 2 funding rounds. Most recently, it raised $30.0M Series B in January 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2021 | $30M Series B | Christian Angermayer | Catalio Capital, Helium 3 Ventures, Inveready Technology Investment Group, MMC Ventures, Platanus Ventures, Presight Capital, Valar Ventures, Christian Woolfenden, Matt Bellamy, Richard Fearn, Cambrian Biopharma, Steve Jurvetson, Pura Vida Investments | Announced |
| Oct 1, 2020 | $29M Series A | — | Helium 3 Ventures, MMC Ventures, Platanus Ventures, Presight Capital, Valar Ventures, Christian Woolfenden, Matt Bellamy, Richard Fearn | Announced |
Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing next-generation immunotherapies, primarily conditionally active antibodies that function selectively in the tumor microenvironment to enhance anti-cancer immune responses.[1][2][3][4] Its key platforms include ImmunoPhage, which uses bacteriophage to target tumor-associated antigens in personalized yet off-the-shelf cancer treatments like the preclinical SNS-401-NG for Merkel Cell Carcinoma, and TMAb, featuring human monoclonal antibodies and alpaca-derived nanobodies such as SNS-VISTA targeting the VISTA immune checkpoint.[1][2] The company serves cancer patients by addressing unmet needs in immunotherapy, with a pipeline of investigational therapies traded publicly as NASDAQ: SNSE, demonstrating growth through platform scalability and manufacturing efficiency.[1][3][4]
Sensei Biotherapeutics emerged as a biopharmaceutical innovator focused on immuno-oncology, though specific founding details like exact year or original founders are not detailed in available sources; it has evolved into a clinical-stage entity with deep expertise in phage-based and antibody platforms.[1][3] The company's idea stems from leveraging the immune system's natural mechanisms—such as bacteriophage to engage immune responses and tumor-selective antibodies—to overcome limitations in traditional cancer treatments.[1][2][4] Pivotal moments include advancing ImmunoPhage's Phortress™ library for multi-antigen targeting and TMAb candidates into preclinical and lead generation stages, supported by a leadership team including business leaders like those with MBAs from Carnegie Mellon and biophysics backgrounds, alongside board members such as James Peyer, Ph.D., founder of longevity biotech firm Cambrian Biopharma.[1][2]
Sensei rides the immuno-oncology wave, capitalizing on advances in tumor microenvironment modulation and phage-based vaccines amid rising demand for precision cancer therapies.[1][2][4] Timing aligns with maturing checkpoint inhibitors and biologics, where market forces like scalable manufacturing needs and personalized medicine favor its off-the-shelf yet adaptable platforms.[1][3] As a clinical-stage player (NASDAQ: SNSE), it influences the biotech ecosystem by pioneering conditionally active antibodies, potentially expanding options for hard-to-treat cancers like Merkel Cell Carcinoma and contributing to broader immunotherapy innovation.[1][3][4]
Sensei Biotherapeutics is poised to advance its pipeline, with preclinical assets like SNS-401-NG and SNS-VISTA potentially entering clinics, driven by immunotherapy trends and immune checkpoint discoveries.[1][2] Evolving regulations, AI-aided drug design, and partnerships could accelerate growth, amplifying its role in cancer treatment ecosystems. As a nimble clinical-stage biotech, its tumor-selective focus positions it to shape next-gen therapies, building on its immune-inspired platforms for sustained impact.[1][4]